The Peptide NewsroomPeptide research, industry and supply-chain headlines

Vancouver Supplier Named Canada's Top Retatrutide Source, but the Ranking Came From a Press Release

Topic card: retatrutide

A press release distributed through GLOBE NEWSWIRE says ResearchedPeptides.ca has been ranked the number one retatrutide supplier in Canada in a 2026 comparison published by Toronto Times. The guide assessed five sources available to Canadian laboratories on analytical transparency and domestic procurement, and the Vancouver company took the top overall placement.

Retatrutide, also known as LY3437943, is a synthetic 39-amino-acid peptide studied as a triple agonist of the GIP, GLP-1 and glucagon receptors. The added glucagon receptor activity is what separates it from dual GIP/GLP-1 agonists such as tirzepatide. The release states plainly that retatrutide is an investigational compound and is not approved for human use.

The purity number

The figure doing the work here is 99.79%, reported by HPLC-UV at 214 nm on a Certificate of Analysis issued by the testing laboratory Testides on May 11, 2026, under report number JSTE-RETA-10-050426. The same document reports a bacterial endotoxin result below 0.125 EU/mL, which the release says passed the USP <85> specification.

According to the release, Toronto Times argued that a specific figure like 99.79% gives a researcher an exact value to record, while a "greater than or equal to 99%" claim only sets a floor. The example given is that samples measuring 99.01% and 99.79% both satisfy the same threshold claim, which is a fair point about how purity marketing works across this entire category.

What a ranking like this is

It is worth being precise about the chain of custody on these claims. A supplier issued a press release about a ranking by a publication, and the analytical result underpinning the ranking comes from a certificate commissioned on that supplier's own batch. None of that is unusual in the research peptide trade, and none of it is independent verification.

The release also credits domestic fulfilment, with orders shipping from British Columbia by Canada Post Xpresspost, typically within two business days across most of Canada, avoiding customs exposure on cross-border orders. Logistics, not chemistry, is doing some of the ranking work.

Bottom line

The release says rankings were determined by the publication, and the products referenced are sold for laboratory research only. The genuinely useful idea buried in a promotional document is that a dated, batch-specific laboratory result tells you more than a threshold claim, and that standard is one buyers in this market could apply to everyone, including the company announcing it.

Source: RSS.app — Peptides bundle. Read the original.

Filed under: glp-1

Comments (0)

Discussion happens on Reddit.
Questions and corrections go to r/PeptideNewsroom.

Go to r/PeptideNewsroom

Corrections are the most useful thing you can post. Comments touching dosing, sourcing or links are held for a moderator first.

More from The Peptide Newsroom

What the Research Actually Says About Semaglutide, From Weight Loss to Memory

Semaglutide has large human trials behind its weight and metabolic outcomes, but the newer questions about energy expenditure, muscle preservation and cognition are far less settled. A digest of what researchers have actually reported, and where the evidence stops.

Kemin Pitches Positive Aging, GLP-1 Support and Gut Health as Its 2027 Trends

Kemin's Filipa Quintela told Nutritional Outlook at SupplySide Global that positive aging, GLP-1 support through Slendesta, and gut health via the Gutopia platform will shape the supplier's 2027 development. She also put American lutein intake at around 2 mg a day against an optimal 10 mg.

Ingredient Supplier Kemin Puts GLP-1 Companion Nutrition at the Center of Its 2027 Outlook

At SupplySide Global, ingredient developer Kemin outlined a 2027 wellness outlook built on GLP-1 companion nutrition, gut health, and positive aging, with FloraGLO Lutein repositioned toward cognition. No trial data or outcome figures appear anywhere in the coverage, which makes this a supplier forecast rather than new evidence.